MZT Matritech,

BOSTON, May 2 /PRNewswire-FirstCall/ -- Scimitar Equity Research, Inc. issues a review on Matritech, Inc. (AMEX:MZT) entitled "Revenue and Net Loss Increased, Guidance is Reaffirmed and Debt Increases the Need to Examine Future Options." The analyst research review is available on Scimitar's website: http://www.scimitarequity.com/. Matritech, Inc is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. MZT's first two products, the NMP22(R) Test Kit and NMP22(R) BladderChek(R) Test, have been FDA approved for the monitoring and diagnosis of bladder cancer. The NMP22 BladderChek Test is based on Matritech's proprietary nuclear matrix protein (NMP) technology, which correlates levels of NMP's in body fluids to the presence of cancer. Beginning with a patent portfolio licensed exclusively from the Massachusetts Institute of Technology (MIT), Matritech's patent portfolio has grown to 14 other U.S. patents. In addition to the NMP22 protein marker utilized in the NMP22 Test Kit and NMP22 BladderChek Test; MZT has discovered other proteins associated with cervical, breast, prostate, and colon cancer. MZT's goal is to utilize protein markers to develop, through its own research staff and through strategic alliances, clinical applications to detect cancer. More information about MZT is available at: http://www.matritech.com/. Scimitar Equity Research, Inc. provides sponsored equity research of the healthcare industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about Matritech, Inc (AMEX:MZT) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures. CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 559-1080 fax: (617) 559-1083 e-mail: DATASOURCE: Scimitar Equity Research, Inc. CONTACT: Henry W. McCusker, Director of Research of Scimitar Equity Research, Inc., +1-617-559-1080, fax: +1-617-559-1083, Web site: http://www.scimitarequity.com/

Copyright